X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6545) 6545
Newsletter (105) 105
Magazine Article (53) 53
Book / eBook (10) 10
Newspaper Article (5) 5
Web Resource (5) 5
Dissertation (2) 2
Book Chapter (1) 1
Book Review (1) 1
Publication (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5973) 5973
female (3613) 3613
diphosphonates - adverse effects (3359) 3359
diphosphonates - therapeutic use (3202) 3202
male (2468) 2468
aged (2162) 2162
bone density conservation agents - adverse effects (2150) 2150
middle aged (2125) 2125
osteoporosis (2087) 2087
bisphosphonates (1936) 1936
bone density conservation agents - therapeutic use (1748) 1748
diphosphonates - administration & dosage (1714) 1714
zoledronic acid (1423) 1423
osteoporosis - drug therapy (1262) 1262
diphosphonates (1177) 1177
risk factors (1114) 1114
bone density conservation agents - administration & dosage (1034) 1034
osteonecrosis - chemically induced (985) 985
endocrinology & metabolism (978) 978
adult (947) 947
alendronate (947) 947
aged, 80 and over (940) 940
treatment outcome (833) 833
bone density - drug effects (827) 827
oncology (816) 816
fractures (813) 813
bone neoplasms - secondary (810) 810
imidazoles - adverse effects (794) 794
bones (793) 793
bisphosphonate (768) 768
orthopedics (753) 753
medicine & public health (749) 749
animals (748) 748
care and treatment (728) 728
postmenopausal women (722) 722
jaw diseases - chemically induced (712) 712
drug therapy (702) 702
diphosphonates - pharmacology (694) 694
pamidronate (691) 691
imidazoles - therapeutic use (689) 689
bone neoplasms - drug therapy (675) 675
dentistry, oral surgery & medicine (644) 644
therapy (639) 639
cancer (636) 636
osteonecrosis (616) 616
osteoporosis, postmenopausal - drug therapy (614) 614
prevention (591) 591
surgery (562) 562
medicine, general & internal (554) 554
women (550) 550
double-blind (547) 547
bone density (545) 545
research (545) 545
phosphonates (544) 544
imidazoles - administration & dosage (539) 539
bone (534) 534
dentistry (534) 534
rheumatology (528) 528
health aspects (527) 527
risk (521) 521
bone-mineral density (511) 511
necrosis (503) 503
retrospective studies (482) 482
time factors (460) 460
administration, oral (459) 459
drug administration schedule (444) 444
osteoporosis - prevention & control (437) 437
analysis (423) 423
risk-factors (413) 413
pharmacology & pharmacy (403) 403
breast neoplasms - drug therapy (402) 402
abridged index medicus (399) 399
fractures, bone - prevention & control (391) 391
infusions, intravenous (391) 391
postmenopausal osteoporosis (378) 378
complications and side effects (366) 366
osteoporosis - chemically induced (363) 363
denosumab (361) 361
dosage and administration (361) 361
breast-cancer (359) 359
breast cancer (344) 344
follow-up studies (340) 340
multiple-myeloma (340) 340
endocrinology (337) 337
jaw (326) 326
bone metastases (325) 325
breast neoplasms - pathology (324) 324
bone density conservation agents - pharmacology (317) 317
density (315) 315
metastasis (310) 310
rats (301) 301
radiography (299) 299
risedronate (295) 295
internal medicine (290) 290
randomized controlled trials as topic (288) 288
child (283) 283
multiple myeloma - drug therapy (279) 279
dose-response relationship, drug (277) 277
glucocorticoids - adverse effects (277) 277
bone remodeling - drug effects (270) 270
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6298) 6298
Japanese (184) 184
German (112) 112
French (82) 82
Spanish (54) 54
Portuguese (24) 24
Italian (23) 23
Chinese (20) 20
Dutch (19) 19
Danish (16) 16
Hungarian (15) 15
Norwegian (12) 12
Polish (12) 12
Russian (10) 10
Czech (6) 6
Swedish (5) 5
Hebrew (4) 4
Arabic (2) 2
Croatian (2) 2
Korean (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2009, Volume 360, Issue 7, pp. 679 - 691
This large trial tested the effect of adding zoledronic acid to adjuvant endocrine treatment... 
BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS | MEDICINE, GENERAL & INTERNAL | BONE LOSS | SOLID TUMORS | TAMOXIFEN | METASTASES | DELTA T-CELLS | RECEPTOR | ADJUVANT THERAPY | POSTMENOPAUSAL WOMEN | AUSTRIAN BREAST | Breast Neoplasms - surgery | Triazoles - adverse effects | Follow-Up Studies | Humans | Middle Aged | Receptors, Estrogen - analysis | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Antineoplastic Agents, Hormonal - therapeutic use | Diphosphonates - therapeutic use | Adult | Female | Chemotherapy, Adjuvant | Imidazoles - therapeutic use | Drug Therapy, Combination | Goserelin - therapeutic use | Aromatase Inhibitors - therapeutic use | Diphosphonates - adverse effects | Triazoles - therapeutic use | Bone Density Conservation Agents - adverse effects | Premenopause | Imidazoles - adverse effects | Bone Density Conservation Agents - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Estrogen Antagonists - therapeutic use | Tamoxifen - therapeutic use | Estrogen Antagonists - adverse effects | Tamoxifen - adverse effects | Nitriles - adverse effects | Nitriles - therapeutic use | Zoledronic acid | Care and treatment | Usage | Breast cancer | Health aspects | Function tests (Medicine) | Chemotherapy | Acids | Womens health | Menopause | Colorectal cancer | Cytotoxicity | Radiation therapy | Cancer therapies | Index Medicus | Abridged Index Medicus
Journal Article
Osteoporosis international, ISSN 1433-2965, 2017, Volume 29, Issue 2, pp. 467 - 478
.... INTRODUCTION: Most of the known adverse drug reactions described for anti-osteoporosis medication (AOM... 
Humans | Middle Aged | Male | Diphosphonates/adverse effects | United Kingdom/epidemiology | Bone Density Conservation Agents/adverse effects | Teriparatide/adverse effects | Denosumab/adverse effects | Thiophenes/adverse effects | Aged, 80 and over | Female | Aged | Risk Assessment/methods | Primary Health Care/methods | Spain/epidemiology | Venous Thromboembolism/chemically induced | Alendronate/adverse effects | Cohort Studies | Pharmacoepidemiology | Anti-osteoporosis medication | Medicine & Public Health | Orthopedics | Rheumatology | Electronic health records | Primary care | Endocrinology | Venous thromboembolism | DATABASE | ENDOCRINOLOGY & METABOLISM | STRONTIUM RANELATE | Risk Assessment - methods | Primary Health Care - methods | Bone Density Conservation Agents - adverse effects | Thiophenes - adverse effects | Denosumab - adverse effects | Alendronate - adverse effects | Spain - epidemiology | Venous Thromboembolism - chemically induced | Teriparatide - adverse effects | Venous Thromboembolism - epidemiology | Diphosphonates - adverse effects | United Kingdom - epidemiology | Osteoporosis | Complications and side effects | Alendronate | Patient outcomes | Diphosphonates | Dosage and administration | Research | Drug therapy | Thromboembolism | Risk factors | Strontium | Alendronic acid | Parathyroid hormone | Estrogen receptors | Raloxifene | Health risk assessment | Bisphosphonates
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 387, Issue 10024, pp. 1163 - 1177
Journal Article
Calcified Tissue International, ISSN 0171-967X, 8/2011, Volume 89, Issue 2, pp. 91 - 104
The pharmacological management of disease should involve consideration of the balance between the beneficial effects of treatment on outcome and the probability of adverse effects... 
Biochemistry, general | Bisphosphonate | Drug–drug interaction | Adverse drug reaction | SERM | Denosumab | Cell Biology | Life Sciences | Osteoporosis | Orthopedics | Strontium ranelate | Endocrinology | Teriparatide | Drug-drug interaction | BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS | BONE-MINERAL DENSITY | ORAL BISPHOSPHONATES | PARATHYROID-HORMONE 1-34 | ESTROGEN-RECEPTOR MODULATOR | ATRIAL-FIBRILLATION | ZOLEDRONIC ACID | LONG-TERM USE | VERTEBRAL FRACTURE RISK | ENDOCRINOLOGY & METABOLISM | Osteoporosis, Postmenopausal - epidemiology | Thiophenes - therapeutic use | Teriparatide - therapeutic use | Bone Density Conservation Agents - adverse effects | Thiophenes - adverse effects | Organometallic Compounds - adverse effects | Humans | Pharmacovigilance | Osteoporosis, Postmenopausal - drug therapy | Bone Density Conservation Agents - pharmacology | Drug-Related Side Effects and Adverse Reactions - epidemiology | Drug Interactions - physiology | Diphosphonates - therapeutic use | Organometallic Compounds - therapeutic use | Female | Teriparatide - adverse effects | Diphosphonates - adverse effects | Medical colleges | Drug interactions | Atrial fibrillation | Menopause | Phosphonates | Estrogen | Postmenopausal women | Complications and side effects | Fractures | Thromboembolism | Health aspects | Public health | Biomedical engineering | Women | Prescription drugs | Side effects | Pharmacology | Drug therapy | Review
Journal Article
Mayo Clinic proceedings, ISSN 0025-6196, 2009, Volume 84, Issue 7, pp. 632 - 638
Journal Article
Journal Article
Mayo Clinic Proceedings, ISSN 0025-6196, 2014, Volume 89, Issue 7, pp. 1026 - 1026
Journal Article
Advances in Chronic Kidney Disease, ISSN 1548-5595, 2011, Volume 18, Issue 3, pp. 214 - 218
Drug and xenobiotic toxicity is an important cause of kidney injury, especially in vulnerable patients. Nephrotoxic syndromes include functional disorders;... 
Nephrology | Syndrome of inappropriate antidiuresis | Interstitial nephritis | Thrombotic microangiopathy | Acute tubular necrosis | Nephrogenic diabetes insipidus | Drug-induced kidney injury | Glomerular disease | Obstructive nephropathy | Fanconi syndrome | Nephrotoxicity | Crystalopathy | Syndrome of inappropriate antidiuresis | TUBULAR DYSFUNCTION | GLOMERULONEPHRITIS | ACUTE-RENAL-FAILURE | TOXICITY | FEATURES | INHIBITION | UROLOGY & NEPHROLOGY | PATIENT | KIDNEY | FANCONI-SYNDROME | TENOFOVIR | Oxalates - adverse effects | Glutamates - adverse effects | Guanine - analogs & derivatives | Antipsychotic Agents - adverse effects | Humans | Thiazoles - adverse effects | Tenofovir | Adenine - adverse effects | Anticonvulsants - adverse effects | Phenindione - adverse effects | Kidney Diseases - chemically induced | Pyrroles - adverse effects | Guanine - adverse effects | Angiogenesis Inhibitors - adverse effects | Diphosphonates - adverse effects | Plants, Toxic - adverse effects | HIV Protease Inhibitors - adverse effects | Dasatinib | Proton Pump Inhibitors - adverse effects | Adenine - analogs & derivatives | Alcohols - adverse effects | Organophosphonates - adverse effects | Serotonin Uptake Inhibitors - adverse effects | Phenindione - analogs & derivatives | Pemetrexed | Indoles - adverse effects | Pyrimidines - adverse effects | Triazines - adverse effects
Journal Article